Legend Biotech Corp
9LB
Company Profile
Business description
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Contact
2101 Cottontail Lane
SomersetNJ08873
USAT: +1 737 317-5050
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2,700
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,828.70 | 56.70 | 0.65% |
CAC 40 | 7,726.26 | 63.67 | 0.83% |
DAX 40 | 23,693.89 | 20.60 | 0.09% |
Dow JONES (US) | 44,494.94 | 400.17 | 0.91% |
FTSE 100 | 8,753.11 | 32.22 | -0.37% |
HKSE | 24,221.41 | 149.13 | 0.62% |
NASDAQ | 20,202.89 | 166.84 | -0.82% |
Nikkei 225 | 39,762.48 | 223.85 | -0.56% |
NZX 50 Index | 12,784.29 | 49.76 | 0.39% |
S&P 500 | 6,198.01 | 0.00 | 0.00% |
S&P/ASX 200 | 8,597.70 | 56.60 | 0.66% |
SSE Composite Index | 3,454.79 | 2.95 | -0.09% |